Storia in 6 fonti

Servier to buy Edgewise Therapeutics' muscular dystrophy drug

The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.

Raccontata da

pharmaceutical-technology.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo21 h fa

Servier to buy Edgewise Therapeutics' muscular dystrophy drug

The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.

originale

endpoints.news21 h fa

Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets

Servier will pick up the muscular dystrophy business from Edgewise Therapeutics, giving the French pharma company access to an experimental neuromuscular medicine that could have pivotal data by year's end.

Leggi questa versione → originale

pharmaceutical-technology.com1 h fa

Servier to buy Edgewise's muscular dystrophy business for $2.65bn

Servier buys Edgewise's muscular dystrophy business for $2.65bn upfront, securing sevasemten (Phase II rare-disease candidate for Duchenne/Becker dystrophy). Highlights biotech M&A consolidation toward regulatory-gated, high-value rare assets; pharma valuations hinge on long-term compliance milestones, reshaping IT infrastructure demand in healthcare sector.

Leggi questa versione → originale

biopharmadive.com1 g fa

Servier buys into muscular dystrophy with potentially $2.7B deal

The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.

Leggi questa versione → originale

investors.com19 h fa

This Biotech Snatched Up $1.55 Billion And Removed A Key Overhang

Edgewise Therapeutics stock rocketed Monday after Servier agreed to buy the biotech's muscular dystrophy business.

Leggi questa versione → originale

lemonde.fr19 h fa

Le laboratoire Servier mise 1,33 milliard d’euros sur des traitements contre les dystrophies musculaires

Le groupe pharmaceutique français rachète l’activité dystrophie musculaire de l’américain Edgewise Therapeutics, incluant un traitement expérimental contre les maladies de Duchenne et de Becker.

Leggi questa versione → originale

Timeline cronologica

lunedì 1 giugno 2026·biopharmadive.com
Servier buys into muscular dystrophy with potentially $2.7B deal
The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.
lunedì 1 giugno 2026·statnews.com
Servier to buy Edgewise Therapeutics' muscular dystrophy drug
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.
lunedì 1 giugno 2026·endpoints.news
Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets
Servier will pick up the muscular dystrophy business from Edgewise Therapeutics, giving the French pharma company access to an experimental neuromuscular medicine that could have…
lunedì 1 giugno 2026·investors.com
This Biotech Snatched Up $1.55 Billion And Removed A Key Overhang
Edgewise Therapeutics stock rocketed Monday after Servier agreed to buy the biotech's muscular dystrophy business.
lunedì 1 giugno 2026·lemonde.fr
Le laboratoire Servier mise 1,33 milliard d’euros sur des traitements contre les dystrophies musculaires
Le groupe pharmaceutique français rachète l’activité dystrophie musculaire de l’américain Edgewise Therapeutics, incluant un traitement expérimental contre les maladies de…
martedì 2 giugno 2026·pharmaceutical-technology.com
Servier to buy Edgewise's muscular dystrophy business for $2.65bn
Servier has signed an agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at up to $2.65bn.